Levetiracetam: new preparation. For some patients with refractory partial epilepsy.
Author information unavailable
Abstract
Author information unavailable
Abstract
According to four placebo-controlled trials, levetiracetam (a piracetam derivative) reduces the frequency of seizures in 20 to 30% of patients with partial epilepsy when added to an existing but inadequate treatment. An indirect comparison suggests that levetiracetam is as effective as other second-line antiepileptics used for combination therapy.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
According to four placebo-controlled trials, levetiracetam (a piracetam derivative) reduces the frequency of seizures in 20 to 30% of patients with partial epilepsy when added to an existing but inadequate treatment. An indirect comparison suggests that levetiracetam is as effective as other second-line antiepileptics used for combination therapy.
Key concepts: Levetiracetam, Piracetam, Refractory (planetary science), Partial epilepsy, Epilepsy, Medicine, partial seizures, Placebo